Canopy Growth posts 13.00 percent revenue growth: Canopy Growth stock has USD 301.6 million value

Published on 10/17/2026 at 19:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Canada medical revenue grew 22.00 percent in the first quarter of fiscal 2027. Canopy Growth stock closed at EUR 0.64 on October 16, 2026.

Revenue growth and market value

Canopy Growth reported 13.00 percent net revenue growth for the first quarter of fiscal 2027 on August 7, 2026.
Canada medical cannabis revenue increased 22.00 percent in the first quarter of fiscal 2027.
Canopy Growth stock closed at EUR 0.64 on Tradegate on October 16, 2026.
Canopy Growth's market capitalization stood at USD 301.6 million on October 16, 2026.

CGC, CA1380357048, Illustration mit AI erstellt.

Canopy Growth reported 13.00 percent net revenue growth in the first quarter of fiscal 2027, including a 22.00 percent increase in Canada medical cannabis revenue, according to Canopy Growth on August 7, 2026. The stock closed at EUR 0.64 on Tradegate on October 16, 2026.

Medical cannabis leads growth

The first-quarter figures show where Canopy Growth's operating momentum was concentrated. Canada medical cannabis revenue rose 22.00 percent, while international cannabis revenue increased 10.00 percent in the same fiscal period, according to the company's investor materials dated August 7, 2026.

The revenue trend came with continuing pressure on profitability. Canopy Growth's operating result was negative USD 22.11 million in the first quarter of fiscal 2027, while net income attributable to common shareholders was negative USD 14.58 million for the period. The figures make revenue quality and cost control more important than growth alone.

Nasdaq range remains wide

On the Nasdaq, Canopy Growth last traded at USD 0.71 on October 16, 2026 at 4:00 p.m. ET. FinancialContent identifies Nasdaq as the primary exchange and reports a 52-week range of USD 0.69 to USD 2.38, leaving the stock 70.00 percent below its 52-week high. Trading volume was 2,409,309 shares against a three-month average of 2.9 million shares.

The wide range puts the current quotation near the lower end of the year's band. The same market page reports a 5.90 percent decline over one week and a 40.10 percent year-to-date decline, both dated October 16, 2026.

November results set the next marker

Canopy Growth is estimated to report its second-quarter fiscal 2027 results on November 6, 2026, before the market opens, with a conference call scheduled for 10:00 a.m. ET, according to MarketBeat. Its listed consensus calls for USD 57.72 million in revenue and negative USD 0.03 earnings per share for that quarter, compared with USD 47.86 million and negative USD 0.01 in the year-earlier period.

The estimate implies a 20.60 percent year-over-year revenue increase, but the projected loss keeps the earnings release central to the market's next assessment. The company also says its global platform is anchored by operations in Canada and Germany.

Comparison with peers

Canopy Growth (Nasdaq, USD): USD 0.71, market capitalization USD 301.6 million.

Tilray Brands (Nasdaq, USD): minus 5.30 percent, market capitalization USD 340.0 million.

SNDL (Nasdaq, USD): plus 3.31 percent, market capitalization USD 307.7 million.

Tradegate close frames the stock

The EUR 0.64 Tradegate close on October 16, 2026 provides the latest German-market reference, while the Nasdaq quotation ended at USD 0.71 on the same date. Canopy Growth's next reported period will test whether the medical cannabis growth rate can persist while losses narrow.

Canopy Growth is a healthcare company focused on cannabis and hemp-derived products across Canada, the United States and Germany. Its business includes medical and adult-use cannabis, extracts, beverages, edibles and related consumer brands.